News | January 06, 2026
Nia Therapeutics unveils first implantable brain interface for memory disorders
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
The FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial offered confirmatory evidence
Elanco expects Befrena to launch in the US in the first half of 2026
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
If approved, imlifidase has the potential to transform the kidney transplant landscape by enabling highly sensitized patients to also have access to a potentially life-changing kidney transplant
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
NUFYMCO BLA has been approved by the USFDA
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
Subscribe To Our Newsletter & Stay Updated
